-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Management of Prolymphocytic Leukemia

Program: Education Program
Session: New Approaches in Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia
Sunday, December 6, 2015, 9:30 AM-11:00 AM
Tangerine 2 (WF2), Level 2 (Orange County Convention Center)
Monday, December 7, 2015, 2:45 PM-4:15 PM
Chapin Theater (W320), Level 3 (Orange County Convention Center)

Claire E Dearden, MD, FRCP, FRCPath

The Royal Marsden Hospital Biomedical Research Centre, London and Surrey, United Kingdom

Disclosures: Dearden: Medimmune: Consultancy ; Infinity: Consultancy ; Janssen: Consultancy , Honoraria ; Gilead: Consultancy , Honoraria ; Roche: Consultancy . Off Label Use: Alemtuzumab to treat PLL.